TY - JOUR
T1 - Adoption of Telemedicine for Postoperative Follow-Up after Inpatient Cancer-Related Surgery
AU - Uppal, Abhineet
AU - Kothari, Anai N.
AU - Scally, Christopher P.
AU - Roland, Christina L.
AU - Bednarski, Brian K.
AU - Katz, Matthew H.G.
AU - Vauthey, Jean Nicholas
AU - Chang, George J.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - PURPOSE:The COVID-19 pandemic has resulted in significant changes in health care delivery, including the rapid adoption of telemedicine across multiple specialties and practice environments. This includes postoperative visits (POV), despite limited data on outcomes following these telemedicine POV. We sought to determine whether these types of visits successfully identify and address postoperative complications when compared with in-person POV.METHODS:This was a retrospective cohort study of patients undergoing elective inpatient cancer-related surgery from March 2020 through December 2020. The exposure variable was type of POV (telemedicine v in-person). The primary outcome was unplanned hospital readmission within 90 days, and secondary outcomes included 30-day readmission, length of stay of first readmission, and mortality.RESULTS:Five-hundred thirty-five patients underwent elective inpatient operations and met our inclusion criteria. Of these, 98 (18.5%) had an initial telemedicine POV. There was no difference in 90-day readmission on the basis of POV type (16.3% telemedicine v 16.5% in-person, P =.99). Reasons for readmission did not differ between patients who underwent a telemedicine POV compared with in-person POV (all P >.05). After adjustment for patients' demographic and clinical factors, telemedicine POV was not associated with 90-day readmission (odds ratio, 0.89; 95% CI, 0.43 to 1.70; P =.77).CONCLUSION:Telemedicine POV use adopted during the COVID-19 pandemic did not increase risk of readmission when compared with in-person visits following inpatient oncologic surgery. These data can help inform policy on the continued use and application of telemedicine after the pandemic.
AB - PURPOSE:The COVID-19 pandemic has resulted in significant changes in health care delivery, including the rapid adoption of telemedicine across multiple specialties and practice environments. This includes postoperative visits (POV), despite limited data on outcomes following these telemedicine POV. We sought to determine whether these types of visits successfully identify and address postoperative complications when compared with in-person POV.METHODS:This was a retrospective cohort study of patients undergoing elective inpatient cancer-related surgery from March 2020 through December 2020. The exposure variable was type of POV (telemedicine v in-person). The primary outcome was unplanned hospital readmission within 90 days, and secondary outcomes included 30-day readmission, length of stay of first readmission, and mortality.RESULTS:Five-hundred thirty-five patients underwent elective inpatient operations and met our inclusion criteria. Of these, 98 (18.5%) had an initial telemedicine POV. There was no difference in 90-day readmission on the basis of POV type (16.3% telemedicine v 16.5% in-person, P =.99). Reasons for readmission did not differ between patients who underwent a telemedicine POV compared with in-person POV (all P >.05). After adjustment for patients' demographic and clinical factors, telemedicine POV was not associated with 90-day readmission (odds ratio, 0.89; 95% CI, 0.43 to 1.70; P =.77).CONCLUSION:Telemedicine POV use adopted during the COVID-19 pandemic did not increase risk of readmission when compared with in-person visits following inpatient oncologic surgery. These data can help inform policy on the continued use and application of telemedicine after the pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85134427067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134427067&partnerID=8YFLogxK
U2 - 10.1200/OP.21.00819
DO - 10.1200/OP.21.00819
M3 - Article
C2 - 35263166
AN - SCOPUS:85134427067
SN - 2688-1527
VL - 18
SP - E1091-E1099
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 7
ER -